Compositions for treatment of dry eye syndrome or corneal wound healing

A composition of cross-linked hyaluronic acid, chondroitin sulfate, and inositol effectively addresses the limitations of current treatments for dry eye syndrome and corneal wound healing by improving tear film stability, promoting wound healing, and enhancing corneal sensitivity.

WO2025062471A1 Publication Date: 2025-03-27D&V FARMA SOCIETA A RESPONSABILITA LTD
4 Cites 0 Cited by

Patent Information

Application Number
PCT/IT2024/050188
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-09-21
Filing Date
2024-09-19
Publication Date
2025-03-27

AI Technical Summary

Technical Problem

Current treatments for dry eye syndrome, corneal wound healing, and enhancing corneal sensitivity are inadequate, as existing tear substitutes do not effectively relieve symptoms, promote wound healing, or improve sensitivity in patients with dry eye syndrome, diabetes, or post-ophthalmic surgery.

Method used

A composition comprising cross-linked hyaluronic acid (CX-HA), chondroitin sulfate (CS), and inositol (Ins) is used for ophthalmic administration, which combines these components in specific percentages to treat dry eye syndrome, promote corneal wound healing, and enhance corneal sensitivity.

Benefits of technology

The combination of CX-HA, CS, and Ins significantly improves tear film stability, reduces dry eye symptoms, promotes faster wound healing, and enhances corneal sensitivity in patients with dry eye syndrome, diabetes, and post-ophthalmic surgery conditions.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to compositions suitable for ophthalmic administration, which are suitable for the treatment of dry eye syndrome-related signs and symptoms to improve corneal wound healing or corneal sensitivity. The compositions suitable for ophthalmic administration, comprise hyaluronic acid, chondroitin sulphate and inositol in defined weight ratios. The invention further relates hyaluronic acid and chondroitin sulphate in combination with inositol for use in a method of dry eye syndrome-related signs and symptoms, to promote corneal wound healing, or to improve corneal sensitivity. The invention further relates to a combination of hyaluronic acid, chondroitin sulphate and inositol for use as a medicament. The invention further relates to hyaluronic acid, chondroitin sulphate and inositol for use in a method to treat corneal wounds due to dry eye or surgery or injury derived. The invention further relates to an ophthalmic kit of parts comprising hyaluronic acid, chondroitin sulphate and inositol.
Need to check novelty before this filing date? Find Prior Art